Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer

Clinical Breast Cancer

Volumn 9, Issue 4, 2009, Pages 219-224

  Kwan, Karen W ^a   Chlebowski, Rowan T ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Dyspareunia; Estradiol; Goserelin; Pruritus; Tamoxifen; Tibolone

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; GOSERELIN; HYDROXYETHYLCELLULOSE; K Y JELLY; POLYCARBOPHIL; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DYSPAREUNIA; HOT FLUSH; HUMAN; LIBIDO DISORDER; POSTMENOPAUSE; PRURITUS; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; VAGINA; VAGINAL DRYNESS; VULVA;

EID: 73349130416     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.037     Document Type: Review

References (50)

1. Chlebowski RT. Optimizing endocrine treatment strategies in postmenopausal women with hormone-receptor positive early breast cancer. Breast Cancer Res Treat 2008; 112(suppl 1):25-34. Epub ahead of print.
2. Chlebowski RT, Kim JA, Col NF. Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. Semin Oncol 2003; 30:776-788
3. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007; 14(suppl 1):S20-40.
4. Mok K, Juraskova I, Friedlander M. The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. Breast 2008; 17:436-440 Epub ahead of print.
5. Jones SE, Cantrell J, Vukelja S, et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 2007; 25:4765-4771
6. Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17:2659-2669
7. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and thirdgeneration aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004; 15:753-760 (Pubitemid 39281298)
8. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004; 22:4261-4271
9. Antoine C, Vandromme J, Fastrez M, et al. A survey among breast cancer survivors: Treatment of the climacteric after breast cancer. Climacteric 2008; 11:322-328
10. Hackley B, Rousseau ME. Managing menopausal symptoms after the Women's Health Initiative. J Midwifery Womens Health 2004; 49:87-95.
11. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007; 14:355-369
12. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998; 92:722-727
13. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997; 15:969-973
14. van der Laak JA, de Bie LM, de Leeuw H, et al. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerised cytometry. J Clin Pathol 2002; 55:446-451
15. Bygdeman M, Swahn M. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996; 23:259-263
16. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994; 61:178-180
17. Willhite LA, O'Connell MB. Urogenital atrophy: Prevention and treatment. Pharmacotherapy 2001; 21:464-480
18. Ganz PA, Greendale GA, Petersen L, et al. Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst 2000; 92:1054-1064
19. Col NF, Chlebowski RT. Risks and benefits of therapy with menopausal hormones versus selective estrogen receptor modulators in peri and postmenopausal women at increased breast cancer risk. Menopause 2008; 15:804-809
20. Trinkaus M, Chin S, Wolfman W, et al. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008; 13:222-231
21. Bellantoni MF, Harman SM, Cullins VE, et al. Transdermal estradiol with oral progestin: biological and clinical effects in younger and older postmenopausal women. J Gerontol 1991; 46:M216-22.
22. Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980; 51:620-625
23. Freedman M, Kaunitz AM, Reape KZ, et al. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 2009; 16:735-741
24. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: Preliminary results. Menopause 2002; 9:179-187
25. Henriksson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996; 174:85-92.
26. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997; 71:73-80.
27. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultralow doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001; 86:2757-2762
28. Rioux JE, Devllin C, Gelfand MM, et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7:156-161
29. Kendall A, Dowsett M, Folkerd E, et al. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17:584-587
30. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009; 16:30-36
31. Bordeleau L, Pritchard K, Goodwin P, et al. Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clin Ther 2007; 29:230-241
32. Col NF, Kim A, Chlebowski RT. Menopausal hormone therapy after breast cancer: A meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005; 7:R535-40.
33. Holmberg L, Anderson H, HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a ran-domised comparison: Trial stopped. Lancet 2004; 363:453-455
34. Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100:475-482
35. von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. J Natl Cancer Inst 2005; 97:533-535
36. Chlebowski RT, Col N. Menopausal hormone therapy after breast cancer. Lancet 2004; 363:410-411
37. Chlebowski RT, Anderson G. Progestins and recurrence in breast cancer survivors. J Natl Cancer Inst 2005; 97:471-472
38. Chlebowski RT, Hendrix SL, Langer RD, et al. Estrogen plus progestin influence on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003; 289:3243-3253
39. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin use in postmenopausal women. N Engl J Med 2009; 360:573-587
40. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295:1647-1657
41. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10:135-146
42. Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005; 51:21-28
43. Eilertsen AL, Karssemeijer N, Skaane P, et al. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. BJOG 2008; 115:773-779
44. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-691
45. Carlson RW, Schurman CM, Rivera E, et al. Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer. J Clin Oncol 2007; 25(suppl):39s (Abstract 1030).
46. Aksoy S, Dizdar O, Altundag K. Definition postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment. Breast 2008; 17:433-435 Epub ahead of print.
47. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365:1687-1717
48. Cuzick J, Forbes JF, Sestak I, et al. Long term results of tamoxifen prophylaxis for breast cancer -96 month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99:272-282
49. Decensi A, Galli A, Veronesi U. HRT opposed to low-dose tamoxifen (HOT study): Rationale and design. Recent Results Cancer Res 2003; 163:104-111
50. IBIS-1 Investigators. First results from the International Breast cancer Intervention Study (IBIS-1) a randomized prevention trial. Lancet 2002; 360:817-824